Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002439475 | SCV002752183 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-12-14 | criteria provided, single submitter | clinical testing | The p.C92Y variant (also known as c.275G>A), located in coding exon 2 of the PTCH1 gene, results from a G to A substitution at nucleotide position 275. The cysteine at codon 92 is replaced by tyrosine, an amino acid with highly dissimilar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV003102184 | SCV003256958 | benign | Gorlin syndrome | 2023-08-19 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV005050574 | SCV005679706 | uncertain significance | Basal cell carcinoma, susceptibility to, 1; Holoprosencephaly 7; Basal cell nevus syndrome 1 | 2024-01-04 | criteria provided, single submitter | clinical testing |